

A Phase 2 Randomized Trial of Neoadjuvant Enoblituzumab versus Standard of Care in Men with High-Risk Localized Prostate Cancer: The Help Elucidate & Attack Longitudinally (HEAT) Prostate Cancer Randomized Study

Status: Recruiting

Eligibility Criteria

Sex: Male

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- confirmed adenocarcinoma of the prostate - an initial prostate biopsy within 3 months of enrollment is available for review, showing at least 3 positive cores, including one with $\geq 50\%$ involvement and Gleason ≥ 8 - radical prostatectomy has been scheduled - see link to clinicaltrials.gov for complete inclusion & exclusion criteria

Exclusion Criteria:

- known lymph node involvement on CT or distant metastases on CT or bone scan; non-adenocarcinoma prostate cancers - previous or concurrent use of radiation, hormonal, biologic, chemotherapy, immunotherapy, experimental agents, 5 α -reductase inhibitors, or systemic corticosteroids - autoimmune diseases requiring systemic immunosuppression; malignancy within the last 3 years; uncontrolled major infections or illnesses

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Prostate Cancer

More Information

Description: This study aims to improve prostate cancer treatment by testing a drug, enoblituzumab, which targets a protein called B7-H3. Previous research suggests it might boost the immune system to fight cancer. The objective is to see if it delays cancer return compared to standard treatment and identify who responds best.

Study Contact: Christopher Warlick - cwarlick@umn.edu

Principal Investigator: Christopher Warlick, MD

Phase: PHASE2

IRB

Number: STUDY00022418

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.